ImmunityBio Hit with Securities Class Action After FDA Warning, Shares Plunge 21%

What happened

ImmunityBio faces a securities class action lawsuit over alleged misleading claims about Anktiva, following an FDA warning letter. The lawsuit seeks to represent investors who bought shares between January 19 and March 24, 2026. Shares dropped 21% on the news, erasing about $2 billion in market cap. The FDA's warning letter cited executive chairman Dr. Patrick Soon-Shiong's efficacy claims as misleading. This legal escalation compounds the ongoing regulatory overhang and threatens to disrupt Anktiva's commercial momentum.

Implication

The lawsuit formalizes the FDA compliance risk into legal liability, increasing the probability of the bear case where the stock falls toward $4.00. Sequential revenue growth in Q2 is now even more critical to offset negative sentiment, but the class action may dampen new site adoption and prescriber confidence. Any additional FDA enforcement or unfavorable legal developments could force a dilutive capital raise, given the company's going-concern disclosure. Conversely, a swift resolution of the FDA warning letter and strong Q2 revenue could restore some credibility, but the lawsuit timeline extends over years. For now, the risk/reward is unfavorable; the WAIT rating remains appropriate, with an attractive entry near $5.50 only if the thesis breakers are avoided.

Thesis delta

The investment thesis now faces a material new risk: securities litigation that may distract management, increase costs, and further erode investor trust. The base case of sustained sequential revenue growth and contained FDA enforcement is challenged by the lawsuit's class period overlapping with the warning letter. The bull case probability decreases as legal overhang adds to regulatory scrutiny; the bear case probability increases to at least 35-40% given the new liability.